A slightly stronger inhibitory effect on tumor size was observed upon treatment in combination with autophagy inhibitor and durvalumab (a PD-L1 inhibitor) as compared to monotherapy with durvalumab (Fig. 7H). Here, CD274 is linked to neoplasm.